Rising Cancer Rates Drive Growth In Cell And Gene Therapy CDMO Market Driver: Leading Transformation in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market in 2025

Which drivers are expected to have the greatest impact on the over the cell and gene therapy contract development and manufacturing organization (cdmo) market's growth?
The increasing number of cancer cases is anticipated to boost the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market in the future. Cancer embodies a series of conditions marked by uncontrolled multiplication and dispersal of abnormal cells within the body. The escalating incidence of cancer can be largely attributed to factors such as aging populations, lifestyle modifications, exposure to harmful environmental elements, and enhanced detection techniques. By formulating and producing innovative, targeted treatments that improve efficiency and patient outcomes, the cell and gene therapy contract development and manufacturing organization (CDMO) plays a pivotal role in reducing cancer prevalence. For instance, Macmillan Cancer Support, a UK-based charity, estimated in October 2022 that the count of individuals in the UK living with cancer is anticipated to surge from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the increasing incidence of cancer propels the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Get Your Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report Here:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What is the future CAGR of the cell and gene therapy contract development and manufacturing organization (cdmo) market, and how will it impact industry expansion?
The market size of the cell and gene therapy contract development and manufacturing organization (CDMO) has seen significant growth recently. It's predicted to surge from $5.41 billion in 2024 to $6.94 billion in 2025, with a compound annual growth rate (CAGR) of 28.2%. Increased technological developments, supportive regulatory environments, more investment, a higher incidence of genetic disorders and a rise in strategic alliances have all contributed to the growth rate during the historic period.

The market size for the contract development and manufacturing organization (CDMO) within the cell and gene therapy sector is projected to undergo tremendous expansion in the coming years. It is predicted to reach a worth of $18.54 billion by 2029, with a compound annual growth rate (CAGR) of 27.8%. Factors contributing to this expected upsurge during the prediction period encompass wider therapeutic usage, evolving regulations, augmented funding, technological advancements, and global partnerships. Moreover, within the same projected timeline, significant trends are predicted to emerge, such as the rising demand for individualized treatments, enhanced automation and digitization, enlargement of manufacturing prowess, development of cutting-edge delivery systems, and a marked emphasis on sustainability and minimizing environmental harm.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

What are the most significant trends transforming the cell and gene therapy contract development and manufacturing organization (cdmo) market today?
Prominent businesses in the cell and gene therapy contract development and manufacturing organization (CDMO) market are intensifying their efforts to broaden their collection of advanced solutions such as PluriMatrix technology. This technology is employed to boost the scalability, efficiency, and quality in the manufacture of cell-based products. It is custom-designed for the mass production of such products. The PluriMatrix technology enables the 3D growth of cells on an industrial scale, reinforcing high output and uniform quality through a systematized, totally regulated, and validated procedure. To illustrate, Pluri, a biotech firm from Israel, unveiled PluriCDMO, a novel business segment delivering cell therapy production services via a contract development and manufacturing organization (CDMO), in January 2024. This recently established branch includes a good manufacturing practice (GMP) cell therapy production facility spread over 47,000 square feet. Pluri's new sector provides a full range of services right from the preliminary preclinical phases to the concluding stages of clinical trials and commercialization. These services encompass process and analytical evolution, escalation, validation, logistics, automation, and comparability studies approved by regulatory bodies, as stated in an announcement by the company. It takes advantage of the firm's advanced PluriMatrix technology to deliver superior cell therapy manufacturing services.

Which key market segments comprise the cell and gene therapy contract development and manufacturing organization (cdmo) market and drive its revenue growth?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented -

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the cell and gene therapy contract development and manufacturing organization (cdmo) market?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

What Is Covered In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report?

•Market Size Forecast: Examine the cell and gene therapy contract development and manufacturing organization (cdmo) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the cell and gene therapy contract development and manufacturing organization (cdmo) market for a structured understanding.
•Key Players Overview: Analyze major players in the cell and gene therapy contract development and manufacturing organization (cdmo) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cell and gene therapy contract development and manufacturing organization (cdmo) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the cell and gene therapy contract development and manufacturing organization (cdmo) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cell and gene therapy contract development and manufacturing organization (cdmo) market.
•Industry Challenges: Identify potential risks and obstacles affecting the cell and gene therapy contract development and manufacturing organization (cdmo) market.
•Competitive Landscape: Review strategic developments in the cell and gene therapy contract development and manufacturing organization (cdmo) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.